<p>The present invention relates to an anhydrous, non-solvated crystalline form of Ortataxel (I) herein referred to as Form (I). This form is characterized by very low tendency to absorb humidity, ease of isolation and prolonged chemical and physical stability. Therefore, it can be advantageously used for the preparation of pharmaceutical compositions for the treatment of cancer.</p>
